Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

PegIFN/RBV. The four trials that make up this program study the combination in treatment-naive, treatment-experienced and HIV/HCV coinfected patients with chronic genotype-1 HCV. Deleobuvir (BI 207127) is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso™ and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

Hepatitis C is a blood-borne infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, approximately 3.2-5.2 million people have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000 -12,000 deaths in the United States per year.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical compa
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or ... cloud-based platform, exchange, and big data solutions in ... launched its mobile app for Healthcare One Pass, ushering ... mobile devices. The Company jointly hosted the launch ceremony ... and Shenzhen News Net.   The mobile app ...
(Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
Breaking Medicine Technology:CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... EDISON, N.J., Dec. 7 Q-Med AB and Oceana Therapeutics, Inc. ... primary endpoints for the treatment of fecal incontinence. , Q-Med AB ... the FDA during the first quarter of 2010 based on the ... result of years of hard work as we developed a product ...
... , SAN DIEGO, Dec. 7 CareFusion (NYSE: ... six new Pyxis® medication management products at the 44th American ... Exhibition Dec. 6 -10 in Las Vegas. , CareFusion is ... Pyxis products rank number one in user satisfaction ratings by ...
Cached Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3
(Date:7/6/2015)... Los Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report ... that by the time they turn age 35 a quarter of all women in the U.S. ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, ...
(Date:7/6/2015)... ... July 06, 2015 , ... Acara Partners, a ... the return of its complimentary educational webinar series for the summer ... creates success for their clients through targeted marketing, sales, digital communications, branding and ...
(Date:7/6/2015)... ... July 06, 2015 , ... Hundreds of ... aesthetic reasons, which is why liposuction regularly ranks among the top five most ... reduction has become more than a way to slim down a silhouette for ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce that ... Award on behalf of the department of Family Practice. , “This award is a ... practicing in. The technology is changing so rapidly and we are also developing new ...
(Date:7/6/2015)... Utah (PRWEB) , ... July 06, 2015 , ... doTERRA, ... Jowers to its executive management team. Most recently, Jowers held the position as Director ... ten years. , After spending a decade building the institute, Jowers states that he ...
Breaking Medicine News(10 mins):Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4
... 23 (HealthDay News) -- A new study says many ... with others, a finding that surprised the researchers. ... health care providers to access their online health information ... author Dr. Donna Zulman, an instructor of medicine at ...
... 23 (HealthDay News) -- Hay fever symptoms -- itchy, watery ... spring than summer even when pollen counts are the same, ... compared daily pollen counts during the 2007 and 2008 hay ... living around Leiden in the Netherlands. The study participants ...
... American Association of Anatomist,s (AAA) Young Investigator,Awards ... Mossmanwith the recently established Morphological Sciences Award, ... of their careers who have made important ... in cell/molecular biology, developmental biology, comparative neuroanatomy, ...
... Wayne State University School of Medicine post-doctoral researcher has ... that triggers a type of breast cancer to transform ... post-doctoral trainee in the Department of Pharmacology, has secured ... Breast Cancer Research Program for his study, "Paracrine Cytokine/Chemokine ...
... , FRIDAY, Dec. 23 (HealthDay News) -- ,Fears ... explain why the percentage of married adults in the United ... study of 122 people in cohabitating couples found that 67 ... fallout of divorce, the University of Central Oklahoma and Cornell ...
... -- The dire physical and mental health effects of ... research about suicidal behavior and injecting meth. In a ... Public Health and the University of British Columbia found ... greater risk of attempting suicide than drug users who ...
Cached Medicine News:Health News:Many VA Patients Would Share Personal Health Records, Study Finds 2Health News:Hay Fever Symptoms Worse in Spring Than Summer: Study 2Health News:Guttman, Radley, Reddien, Reiter receive young investigator awards from anatomy society 2Health News:Wayne State receives DOD grant; study may give insight to slow or halt breast cancer 2Health News:More than other drugs, injected meth is associated with an increased risk of attempted suicide 2
... Captique is a non-animal stabilized ... newest HA filler to enter the ... correction of moderate to severe facial ... folds). Captique is injected just under ...
... Radiesse brings you into the new ... can now offer your patients immediate, long-term ... and flexibility. This injectable filler offers superior ... cosmetic and reconstructive treatments. Long-lasting, Radiesse saves ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... clinically proven to reduce the appearance of ... formula combines Retinol, the purest form of ... It works deep within skin's surface to ... appearance. Fast absorbing, it has a fresh, ...
Medicine Products: